You are here

Article Text

Article menu

See original article:

This article has a correction. Please see:

Download PDFPDF
PostScript
Letters to the Editor
Authors' reply
  1. Shervin R Dashti1,
  2. Cameron G McDougall2
  1. 1Norton Healthcare, Norton Neuroscience Institute, Louisville, Kentucky, USA
  2. 2Division of Neurological Surgery, Barrow Neurological Institute, Phoenix, Arizona, USA
  1. Correspondence to Dr C G McDougall, Division of Neurological Surgery, Barrow Neurological Institute, 350 W. Thomas Road, Phoenix, Arizona 85013, USA; neuropub{at}dignityhealth.org

https://doi.org/10.1136/neurintsurg-2012-010332

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Coutinho et al1 for their comments on our manuscript. They state that the 4% mortality associated with non-invasive anticoagulant treatment in the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) is superior to our observed mortality rate of 15% (two of 13 patients). The ISCVT is a large prospective trial, which is detailed in the discussion section of our article. A direct comparison of mortality rates between …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles